This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Analysis of entities with the lowest risk in crypto, plus how to interpret liquidity, use case maturity, and developer activity for safer bets.
28,397 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
A major fund just increased its stake in Molina Healthcare, while the stock trades lower. This guide breaks down what...
Nvidia's latest investor update can signal big moves for the stock, but the right move depends on your goals, risk to...
Iran slams U.S. strikes drew an immediate market response, with oil prices edging higher and risk assets tightening a...
As policy changes from lenders and the GSEs take shape, mortgage markets face a potential major shift in credit alloc...
SpaceX captures headlines with bold tech and presumed multi-bagger upside. Still, the stock question isn’t simple. Th...
SpaceX stunned markets with a massive IPO haul and a rapid follow-up bond issue. This article breaks down what happen...
In the first half, AMD and Intel outpaced Nvidia as investors rotated into laggards. This article breaks down what ha...
ARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
SpaceX fans and market watchers saw the stock quietly drift lower toward the mid-$120s. This piece breaks down why th...
Two Vanguard growth options vie for dominance in a shifting market. This guide breaks down vanguard growth growth etf...
As AI accelerates, real-world bottlenecks shape growth and risk for investors. This guide digs into bottlenecks build...